Heritable Agriculture, Annogen Agri collaborate on functional annotation to accelerate maize trait development
Agri Heritable Agriculture, Annogen Agri collaborate on functional annotation to accelerate maize trait development Amsterdam, The Netherlands & San Carlos, CA, U.S.A. Heritable Agriculture and Annogen Agri B.V. today announced a collaboration to functionally annotate non-coding variants in maize. Annogen will apply its SuRE™ platform to measure, directly in plant protoplasts, how these non-coding variants […]
Major acceleration of Annogen’s SuRE technology in seed and ag-biotech sector
Agri Major acceleration of Annogen’s SuRE technology in seed and ag-biotech sector 27 July 2026 Annogen is launcing its proprietary SuRE™ platform, which is used for functional annotation and improvement of promoters and enhancers, for applications in crop engineering. The powerful platform provides a massive-scale “blueprint” of a crop’s genetic regulatory landscape to pinpoint the specific […]
VectorY’s VTx-002, featuring an Annogen promoter, cleared for ALS clinical trials phase 1&2
Advanced therapies VectorY’s VTx-002, featuring an Annogen promoter, cleared for ALS clinical trials phase 1&2 27 July 2026 Annogen is proud to announce a major milestone for our partner, VectorY Therapeutics, following the U.S. FDA’s IND clearance to proceed with the PIONEER-ALS Phase 1/2 Trial of VTx-002. This first-in-class vectorized antibody targets pathological TDP-43, the protein driving up […]
JURA Bio and Annogen Announce Research Collaboration to Advance Precision Gene Expression Engineering Through AI-Driven Design and Functional Genomics
Partnership brings together JURA’s variational synthesis platform and Annogen’s SuRE™ technology to unlock new possibilities for safer, more effective advanced therapies.
Annogen Heads to London for the Advanced Therapies Congress 2026
Annogen is excited to confirm our attendance at the upcoming Advanced Therapies Congress, scheduled for March 17th – 18th, 2026, at ExCeL London!
See you at Plant, Animal Genomics (PAG33) in San Diego!
Annogen is thrilled to announce our participation in the upcoming Plant & Animal Genome (PAG 33) conference, taking place from January 10-14, 2026, in beautiful San Diego, California!
Lentitek and Annogen join forces to improve the quality and safety of T-cell therapies
A collaboration announced at the CGTI Leadership Summit aims to improve lentivirus-based CAR-T therapies by eliminating undesired transgene expression during viral vector manufacturing.
Annogen is heading to ESGCT 2025!
Annogen is thrilled to announce our participation in the upcoming European Society of Gene and Cell Therapy (ESGCT) conference, taking place from October 7th to 10th in Seville, Spain.
T-cell promoter data presented at CGTI Leadership Summit
Chief Strategy Officer Martijn Kelder speaks at the Cell and Gene Therapy Innovation Leadership Summit in Barcelona, revealing novel data on Annogen’s validated T-cell specific promoters.
Ascend Advanced Therapies and Annogen Collaborate to Improve AAV Production
Ascend Advanced Therapies and Annogen will combine their expertise in AAV biology, vector manufacturing and genetic engineering to improve the quality of recombinant AAV particles used in gene therapy applications.
